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Abstract
Background: Chemotherapy is an important therapeutic approach for non-small cell lung cancer (NSCLC).
However, a successful long-term treatment can be prevented by the occurring of chemotherapy resistance
frequently, and the molecular mechanisms of chemotherapy resistance in NSCLC remain unclear. In this study,
abnormal expressions of miR-17 and miR-92 families are observed in cisplatin-resistant cells, suggesting that
miR-17 and miR-92 families are involved in the regulation of cisplatin resistance in NSCLC.
Methods: miRNA microarray shows that miR-17 and miR-92 families are all down-regulated in cisplatin-resistant A549/
DDP cells compared with cisplatin-sensitive A549 cells. The aim of this study is to investigate the regulatory functions
of miR-17 and miR-92 families on the formation of cisplatin resistance and the predictive functions of them
as biomarkers of platinum-based chemotherapy resistance in NSCLC.
Results: The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of
CDKN1A and RAD21. As a result of high expressions of CDKN1A and RAD21, the inhibition of DNA synthesis and the
repair of DNA damage are achieved and these may be two major contributing factors to cisplatin resistance.
Moreover, we demonstrate that the expressions of miR-17 and miR-92 families in NSCLC tissues are significantly
associated with platinum-based chemotherapy response.
Conclusion: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and
can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy
in NSCLC.
Keywords: Non-small cell lung cancer, miR-17 and miR-92 families, Cisplatin resistance, G1 phase arrest, DNA
repair
Background
Lung cancer is the highest morbidity and mortality
cancer in the world, and about 80 % cases are non-
small cell lung cancer (NSCLC). In NSCLC, about
70–80 % cases are diagnosed at advanced stage and
lost the opportunity of surgery, and chemotherapy is
the main treatment for these cases. However, by using
chemotherapy, the long term survive rate of NSCLC
is only 10–15 %, and chemotherapy resistance is one of
the main reasons leading to the failure of chemotherapy
[1, 2]. Although numerous mechanisms of chemotherapy
resistance have been described, it is still not fully elu-
cidated at present [3–5]. Therefore, the research of
chemotherapy resistance is important for the success-
ful chemotherapy of NSCLC.
MicroRNA (miRNA) is a kind of endogenous small
non-coding RNA, and it has been found that miRNAs
play important roles in the regulation of gene expression
at the post-transcriptional level through base pairing to
the 3’ untranslated region (3’-UTR) of target messenger
RNA (mRNA) [6]. Currently, more than 1000 miRNAs
among human genome have been discovered. miRNAs
are involved in a variety of basic biological processes,
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and a lot of miRNAs have been found can affect the de-
velopment of cancer as oncogenes or tumor suppressor
genes depending on their targets [7–9]. The miR-17 ~ 92
cluster and paralogous, which are recognized as typical
oncogene-type miRNAs, have been shown to promote
tumorigenesis of many cancer types, such as lung cancer,
medulloblastoma, leukaemia, hepatocellular carcinoma
and so on [10–12].
Cisplatin is a very common chemotherapeutic drug for
anticancer chemotherapy. In general, cisplatin-induced
cytotoxicity can trigger the cellular apoptosis and produce
therapeutic effects [13]. However, during chemotherapy
with cisplatin, it tends to develop cisplatin resistance fre-
quently as a result of the defects in cellular functions, such
as drug absorption, cell proliferation, cell apoptosis, DNA
repair, and other biological process still unknown [14]. Re-
cently, miRNAs also have been found play important roles
in chemotherapy resistance [15–19]. Here, we find that
both miR-17 and miR-92 families, two families of miR-
17 ~ 92 cluster and paralogous, are down-regulated ex-
pressions in cisplatin-resistant A549/DDP cells compared
with cisplatin-sensitive A549 cells. The low expressions of
miR-17 and miR-92 families can result in the high expres-
sions of target genes CDKN1A (cyclin-dependent kinase
inhibitor 1A) and RAD21 (Rad21 homolog (S. pombe)).
CDKN1A can arrest cells at G1 phase and RAD21 can en-
hance the DNA repair, so that A549/DDP cells can avoid
cisplatin-induced cytotoxicity by reducing DNA synthesis
and DNA damage. Moreover, the low expressions of
miR-17 and miR-92 families in NSCLC tissues are asso-
ciated with platinum-based chemotherapy resistance. In
a word, our results demonstrate that both miR-17 and
miR-92 families are involved in the regulation of cis-
platin resistance and may have potential as new bio-
markers for predicting platinum-based chemotherapy
resistance in NSCLC.
Methods
Cell lines and cell culture
Human non-small-cell lung cancer cells A549 (parental)
and A549/DDP (cisplatin-resistant) were cultured in
RPMI 1640 medium supplemented with 10 % fetal bo-
vine serum at 37 °C in a humidified atmosphere with
5 % CO2. A549/DDP cells were induced by using pro-
gressive concentration of cisplatin as described previ-
ously [20]. Cisplatin (1 μg/ml) was also added for the
culture of A549/DDP cells.
Tissue sample collection
NSCLC tissues were collected from the Cancer Center
of Guangzhou Medical University (Guangzhou, China)
with informed consent and Institutional Review Board
(IRB) permission. Thirty-nine NSCLC patients were re-
cruited for this study. All of the following criteria were
met: patients who suffered from primary NSCLC; a
histological diagnosis of NSCLC with at least one meas-
urable lesion; a TNM clinical stage of IIIB to IV; first-
line chemotherapy with platinum-based chemotherapy
every 3 weeks for a maximum of 4 cycles. Fresh NSCLC
tissues were obtained by aspiration biopsy before chemo-
therapy and immediately snap-frozen in liquid nitrogen.
NSCLC tissues were stored in liquid nitrogen until use.
All clinical and biological data were available for the
samples.
According to the RECIST (Response Evaluation Criteria
in Solid Tumors), tissue samples were divided into two
groups according to the patient’s responses assessed by
medical image analysis and detection of serum tumor
markers after 4 cycles of the platinum-based chemo-
therapy: response or partial response, at least 30 %
decrease in the sum of diameters of target lesions from
pre-chemotherapy levels, taking as reference the baseline
sum diameters; stable or progressive disease, decrease of
less than 30 % or increase from pre-chemotherapy levels,
taking as reference the baseline sum diameters. Patients
with chemotherapy response or partial response were
considered as chemotherapy sensitivity (R, responder),
whereas patients with stable or progressive disease were
grouped together as chemotherapy resistance (NR, non-
responder).
All patients provided written informed consent. This
study was approved by the ethics committee of Cancer
Center of Guangzhou Medical University (Approval no.
(2014) 66).
Microarray detection of miRNA expression
The microarray assay and result analysis were performed
as described previously [20]. Briefly, the total RNA of
A549 cells and A549/DDP cells were isolated by Total
RNA Purification Kit. The microarray hybridization as-
says were carried out in two experimental repeats of the
RNA samples obtained from A549/DDP cells (Cy5-la-
beled) and A549 cells (Cy3-labeled). Hybridization images
were collected using a laser scanner and digitized using
Array-Pro image analysis software. Data were analyzed by
first subtracting the background and then normalizing the
signals using an LOWESS filter.
RNA extraction and RT-PCR
Total RNA of cells and tissue samples were extracted
by Trizol (Invitrogen, USA) according to the manu-
facturer’s instruction. Quantitative real time polymer-
ase chain reaction (RT-PCR) was performed by using
ABI ViiATM7Dx Real-Time PCR System (Life Tech-
nologies, USA). For mRNA detection, 1 μg total RNA
was used for cDNA synthesis using a Reverse Tran-
scription Kit (Takara, Japan), then cDNA was used
for RT-PCR using primers and SYBR Green Realtime
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PCR Master Mix (TOYOBO, Japan). For miRNA de-
tection, 1 μg total RNA was used for cDNA synthesis
using a miScript II RT Kit (Qiagen, Germany), then
cDNA was used for RT-PCR using miScript Primer
Assay (Qiagen, Germany) and miScript SYBR Green
PCR Kit (Qiagen, Germany). Expression levels of
mRNA and miRNA were normalized by β-Actin and
U6 (Sigma, USA) separately.








Dual luciferase report system detection of target genes
The wild type (WT) and mutant type (MUT) 3’-UTR
of CDKN1A and RAD21 were chemically synthesized
and inserted into psiCHECK™ -2 vector (promega, USA)
for getting psiCHECK™-2-CDKN1A-3’-UTR or psi-
CHECK™-2-RAD21-3’-UTR (WT or MUT). Dual lucifer-
ase analysis was performed as described previously [20].
Briefly, for miRNA mimics assay, 50 ng plasmids DNA
were transfected in combination with 1.5 nmol of the
miRNA mimics or notarget control (NC) using Lipofec-
tamine Transfection Reagent (Invitrogen of life). For
mRNA protector assay [21], the mRNA protectors for
CDKN1A and RAD21 were designed as complementary
sequences covering the miRNA binding sites in their 3’-
UTRs, and they were inserted into the pCDNA3.1 vec-
tor for the luciferase assay in a 3:1 ratio (protector :
miRNA mimic). In addition, the mRNA protectors for
CDKN1A and RAD21 were inserted into the pCAGIG
vector for the transfection assay in the subsequent. Lucif-
erase activity was measured 48 h after transfection using
the Dual Luciferase Reporter Assay System (Promega).
The cytotoxicity influence of miRNAs
According to the manufacturer’s protocol, 100 nM of
miRNA mimics, miRNA protectors, siRNAs or notarget
control miRNAs (NC) were transfected into cells by Li-
pofectamine Transfection Reagent (Invitrogen of life).
Quantitative cytotoxicity analysis of cisplatin resistance
level was determined by using CCK8 (CCK-8, Dojindo
Laboratories, Japan) and represented in IC50 (μg/ml) as
described previously [20]. Briefly, the suspensions of
cells were incubated with different concentrations of cis-
platin. After 48 h, after the medium with cisplatin were
removed, RPMI1640 medium (Gibco, USA) of 90 μL
and CCK-8 solution of 10 μL were added into each well
of the plate. The cells on the plate were incubated for
3–6 h in the incubator. The absorbance at 450 nm wave-
length was measured on an automated reader (TECAN,
Switzerland).
Western blotting
The cells were harvested at 72 h after transfection of 50
nM of miRNA mimics or miRNA protectors, and lysed
by RIPA buffer for 30 min at 4 °C. 50 μg proteins were
loaded into 15 % SDS–PAGE for analysis. The first anti-
body was rabbit polyclonal anti-CDKN1A or anti-RAD21
(purchased by cell signaling USA, 1:1000 dilutions). The
secondary antibody was goat-anti-rabbit IgG conju-
gated with HRP (horseradish peroxidase) with a dilu-
tion of 1:1000. The bound antibodies were detected
using ECL Plus Western Blotting Detection system (GE
Healthcare). β-Actin was used as an internal control.
Apoptosis analysis
A549/DDP cells were transfected with 50 nM of miRNA
mimics, miRNA protectors or siRNAs in 60 mm petri
dish. 24 h after transfection, cisplatin (2 μg/ml) was
added to each petri dish and the cells were cultured for
24 h. According to the manufacturer’s protocol, cell
apoptosis was detected using an Annexin V-FITC
apoptosis detection kit (BD, USA) by flow cytometric
analysis.
Cell cycle assay
A549/DDP cells or A549 cells were transfected with 50
nM of miRNA mimics, miRNA protectors or siRNAs in
60 mm petri dish. 48 h after transfection, cells were
stained with propidium iodide (PI) for cell cycle analysis
by flow cytometry.
EdU assay
A549/DDP cells or A549 cells were transfected with 50
nM of miRNA mimics, miRNA protectors or siRNAs in
96-well plates. 48 h after transfection, the cells were
added by 100 mM EdU (5-ethynyl-2’-deoxyuridine) and
cultured for an additional 2 h according to the protocol
(Cell Light EdU DNA imaging Kit). Then, the cells were
stained with Hoechst (5 mg/ml) for 30 min. Images were
taken and analyzed by High Content Imaging Pathway
855 (BD, USA). EdU positive ratio was calculated by
(EdU add-in cells/Hoechst stained cells) × 100 % [22].
Immunofluorescent microscopy
A549/DDP cells or A549 cells were transfected with 50
nM of miRNA mimics, miRNA protectors or siRNAs in
6-well culture plate. 24 h after transfection, cells were
treated with cisplatin (2 μg/ml) for 24 h, washed with
PBS and fixed in 4 % paraformaldehyde for 10 min at
room temperature. Fixed cells were washed with PBS,
and permeabilized in 0.25 % Triton X-100 for 10 min.
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After treatment with 5 % BSA blocking agents for a
minimum of 30 min at room temperature, samples were
incubated with a rabbit monoclonal anti-γH2AX anti-
body (1:1000) for 2 h, followed with FITC-conjugated
goat-anti-rabbit secondary antibody (1:500) for 1 h. Cells
were counterstained with 4,6 diamidino-2-phenylindole
(DAPI) for 15 min, washed with PBS and mounted.
Fluorescence images were captured using an Olympus
AX70 fluorescent microscope (Olympus, Tokyo, Japan).
γH2AX foci in each cell (60–100 cells) was counted dur-
ing the imaging process, and we used a setting as a
standard for quantification in the selected cells to ex-
clude relatively weak foci and background spots. In at
least two independent experiments for each data point,
samples were coded to prevent any bias.
Statistical analysis
All values were expressed as mean ± standard deviation
(SD) from at least three separate experiments. IC50
value was assessed by profit regression analysis. Student’s
unpaired t-test, Mann–Whitney U test, chi-square test,
log-rank statistic and Receiver Operating Characteristic
(ROC) were performed using SPSS 21.0 statistical soft-
ware (IBM). A two-tailed P value test was used in all
analyses, and difference was considered as statistically
significant if the P value was less than 0.05 (P < 0.05).
Results
Low expressions of miR-17 and miR-92 families are
associated with cisplatin resistance
Generally, miRNAs are produced from several genomic
miRNA gene clusters and can be classified into different
miRNA family based on the 6-nucleotide seed sequence
similarities. For the miR-17 ~ 92 cluster and paralogous,
there are 16 mature miRNAs which can be categorized
into miR-17, miR-18, miR-19, and miR-92 families ac-
cording to their conserved seed sequences (Fig. 1a). We
have examined the expression levels of miRNAs in
cisplatin-resistant cells (A549/DDP cells) and cisplatin-
sensitive cells (A549 cells) using the microarray analysis
assay in our previous study (20). It was found that 9
miRNAs of miR-17 ~ 92 cluster and paralogous (miR-20b,
miR-20a, miR-17, miR-106a, miR-92b, miR-92a, miR-93,
miR-25, miR-106b) were all down-regulated expressions
in A549/DDP cells compared with A549 cells (Additional
file 1: Table S1). Among these 9 miRNAs, 6 miRNAs be-
long to the miR-17 family and 3 miRNAs belong to the
miR-92 family. Furthermore, the low expressions of miR-
17 and miR-92 families in A549/DDP cells were further
validated by using RT-PCR, and all of them were consist-
ent with the microarray analysis results (Fig. 1b).
To confirm the regulatory functions of miR-17 and
miR-92 families on cisplatin resistance, we altered the
expressions of these miRNAs in A549/DDP cells by
introducing miRNA mimics. As the regulatory functions
of miR-17, miR-20a, miR-20b have been detected before,
the remaining 6 miRNAs are detected in this study [20].
Over-expressions of miR-106a, miR-92b, miR-92a, miR-
93, miR-25 and miR-106b restored sensitivity to cisplatin
in A549/DDP cells, and the IC50 of cisplatin decreased
from 9.71 ± 0.33 μg/ml to 5.17 ± 0.19 μg/ml (miR-106a),
6.08 ± 0.27 μg/ml (miR-92b), 6.25 ± 0.42 μg/ml (miR-92a),
5.53 ± 0.15 μg/ml (miR-93), 6.91 ± 0.36 μg/ml (miR-25)
and 6.36 ± 0.45 μg/ml (miR-106b), as evidenced by the
growth inhibition curve (Fig. 1c). Moreover, we exam-
ined the effects of miR-17 and miR-92 families on
cisplatin-induced cellular apoptosis by using flow cyto-
metric analysis. Based on the 6-nucleotide seed se-
quence similarities, we used miR-17 and miR-92a to
represent these two families separately. Compared to
the notarget control (NC), transfection of miR-17 or
miR-92a mimics increased the cisplatin-induced cellu-
lar apoptosis in A549/DDP cells (Fig. 1d). These results
suggested that low expressions of miR-17 and miR-92
families could maintain the cisplatin resistance in
A549/DDP cells. Therefore, it is hypothesized that both
miR-17 and miR-92 families play important roles in cis-
platin resistance of NSCLC.
Regulation of CDKN1A and RAD21 by miR-17 and miR-92
families
As miRNAs function by silencing target genes, we pre-
dict the targets of miR-17 and miR-92 families by using
picTar and TargetScan prediction systems. In addition
to TGFβR2 (transforming growth factor beta receptor
2) which has been found in our previous study [20], we
find that the 3′ untranslated region (3′-UTR) of
CDKN1A contains two miR-17 family binding sites and
3′-UTR of RAD21 contains one miR-17 family binding
site and one miR-92 family binding site (Fig. 2a). In
order to verify the putative target genes of miR-17 and
miR-92 families by the dual-luciferase reporter assay,
site-directed mutagenesis (MUT) were performed in
the 3′-UTR of CDKN1A and RAD21 (Fig. 2a). Com-
pared with the MUT 3′-UTR control, miR-17 and miR-
92a mimics could decrease the relative luciferase activ-
ity by binding to the target site in WT 3′-UTR of
CDKN1A and RAD21 (Fig. 2b). As shown in Fig. 2c and
d, the expressions of CDKN1A and Rad21, which were
all higher in A549/DDP cells compared with A549 cells,
decreased significantly after the transfection of miR-17
mimics in A549/DDP cells. It was also observed that
the expression of Rad21 decreased significantly after
transfection of miR-92a mimics in A549/DDP cells
(Fig. 2d). Furthermore, transfections of si-CDKN1A
and si-RAD21 could reduce resistance to cisplatin in
A549/DDP cells, and combined transfection of both si-
CDKN1A and si-RAD21 could reduce resistance to
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cisplatin more significantly compared to transfection of
single si-CDKN1A or si-RAD21 (Fig. 2e).
To validate the targeting effect of miR-17 and miR-92
family on CDKN1A and RAD21, we use CDKN1A
mRNA protectors and RAD21 mRNA protectors, which
are complementary sequences that bind to the 3′-UTR
of CDKN1A and RAD21 and block access to the
binding sites of miR-17 and miR-92 family (Fig. 3a).
The mRNA protector can compete with endogenous
miRNAs for the binding site, with higher affinity to pre-
vent miRNA/mRNA association [21]. As expected,
CDKN1A and RAD21 protectors showed blocking ef-
fects on the silencing activities of miR-17 and miR-92a
to CDKN1A and RAD21 by luciferase assays (Fig. 3b).
Fig. 1 Both the miR-17 and miR-92 families were down-regulated in cisplatin resistance cells (a) Schematic representation of the four families of
the miR-17 ~ 92 cluster and paralogous. miRNAs sharing the same seed sequence and involving in the same family were represented by boxes of
the same pattern. b Down-regulation of miR-17 and miR-92 families in microarray experiments was validated by RT-PCR analysis. c Over-expression of
different miRNA of miR-17 and miR-92 families decreased cisplatin resistance of A549/DDP cells significantly. d Apoptosis assays induced by cisplatin
(2 μg/ml) were observed in different miRNA mimics treated A549/DDP cells. (n = 3, *P < 0.05)
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The transfection of CDKN1A and RAD21 protectors in
A549 cells resulted in phenotypes similar to the up-
regulation of CDKN1A and RAD21 and increased resist-
ance to cisplatin (Fig. 3c and d). Same as the results in
A549/DDP cells, combined transfection of both CDKN1A
and RAD21 protectors also could increase resistance to
cisplatin more significantly compared to transfection of
single CDKN1A protectors or RAD21 protectors (Fig. 3d).
These results suggested that CDKN1A and RAD21 were
two direct target genes of miR-17 and miR-92 families and
the high expressions of CDKN1A and RAD21 could com-
binedly promote the cisplatin resistance in NSCLC.
Fig. 2 The miR-17 and miR-92 families regulated cisplatin resistance by targeting CDKN1A and RAD21. a Mutations were generated in the 3′-UTR
sequence of CDKN1A and RAD21 which located in the complementary site for the seed region of miR-17 and miR-92a as indicated. b Luciferase
assays were used to observe the targeting effects of miR-17 and miR-92a on the 3′-UTR of CDKN1A and RAD21. c The protein and mRNA expression
levels of CDKN1A and RAD21 in A549/DDP cells were significantly higher than those in A549 cells, detected by Western Blotting and RT-PCR assays.
d The protein and mRNA expression levels of CDKN1A and RAD21 were decreased in A549/DDP cells after transfection of miR-17 and miR-92a mimics.
e To varying degrees, individual or combined inhibition of CDKN1A and RAD21 by siRNA decreased cisplatin resistance of A549/DDP cells significantly.
(n = 3, *P < 0.05)
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The inhibition of DNA synthesis as G1 phase arrest is
regulated by targeting CDKN1A
It has been showed that CDKN1A can act as a cell-
cycle regulatory gene by inhibiting the activity of
cyclin-CDK2 or cyclin-CDK4 complexes and blocking
DNA synthesis [23]. Firstly, we compared the cell cycle
status of A549 cells and A549/DDP cells by flow cy-
tometry and found that A549/DDP cells were more ar-
rest at G1 phase (>2-fold) (Fig. 4a). Then, in order to
investigate whether the effect of miR-17 and miR-92
families on cisplatin resistance was related to cell cycle
control, we analyzed the cell cycle of A549/DDP cells
transfected with miR-17 mimics, miR-92a mimics, si-
CDKN1A and si-RAD21. According to the results, both
miR-17 mimics and si-CDKN1A could reduce G1 arrest
(~0.6-fold) in A549/DDP cells (Fig. 4b). Our results in-
dicated that low expression of miR-17 family in A549/
DDP cells could trigger G1 phase arrest by targeting
CDKN1A. We next conducted an EdU assay to detect
the DNA synthesis of A549/DDP cells. EdU is a nucleo-
side analog of thymidine and is incorporated into DNA
during active DNA synthesis, and the DNA synthesis
(the proportion of cells incorporating EdU) can be dir-
ectly measured by using EdU [22]. As shown in Fig. 4c,
the transfection of miR-17 mimics or si-CDKN1A re-
sulted in ~1.5-fold increase in the proportion of A549/
DDP cells with DNA synthesis. We also transfected
CDKN1A mRNA protectors in A549 cells, and as a
Fig. 3 CDKN1A and RAD21 mRNA protectors specifically blocked the silencing effects of miR-17 and miR-92 families on the 3′-UTR of CDKN1A and
RAD21. a CDKN1A and RAD21 mRNA protectors that could block the binding of miR-17 and miR-92a to their 3′-UTR were designed respectively.
b CDKN1A and RAD21 mRNA protectors rescued the reduction of luciferase activities caused by the miR-17 and miR-92a targeting effect on
their 3′-UTR respectively. c The protein and mRNA expression levels of CDKN1A and RAD21 were increased in A549 cells after transfection of
CDKN1A and RAD21 mRNA protectors, detected by Western Blotting and RT-PCR assays. d To varying degrees, individual or combined transfection of
CDKN1A and RAD21 mRNA protectors led to increased cisplatin resistance of A549 cells significantly. (n = 3, *P < 0.05)
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Fig. 4 (See legend on next page.)
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result, more A549 cells were arrested at G1 phase
(~1.5-fold) and the proportion of A549 cells with DNA
synthesis also decreased significantly (~0.7-fold) (Fig. 4d
and e). Our results supported the idea that low expres-
sion of miR-17 family could arrest cells at G1 phase
and inhibit DNA synthesis by the specific regulation on
CDKN1A.
The repair of DNA damage is regulated by targeting Rad21
RAD21, as a cohesin subunit, can regulate chromosome
segregation in eukaryotes and is also involved in DNA
repair through homologous recombination [24]. There-
fore, we examined whether miR-17 and miR-92 families
regulated DNA repair in A549/DDP cells by targeting
RAD21. As phosphorylated histone H2AX (γH2AX) is
an early participant in the cisplatin-induced DNA double-
strand breaks (DSBs), we evaluated γH2AX foci formation
assay to determine the degree of cisplatin-induced DNA
damage. After cisplatin treatment, the cisplatin-induced
γH2AX foci in A549/DDP cells were significantly lower
than those in A549 cells (Fig. 5a). Moreover, transfections
of miR-17 mimics, miR-92a mimics or si-RAD21 in-
creased the cisplatin-induced γH2AX foci in A549/DDP
cells, and transfection of RAD21 mRNA protectors re-
duced the cisplatin-induced γH2AX foci in A549 cells
(Fig. 5b and c). It was indicated that low expressions of
miR-17 and miR-92 families could promote the repair of
cisplatin-induced DNA damage by increasing the expres-
sion of RAD21.
The combined predictive function of miR-17 and miR-92
families on cisplatin resistance of NSCLC
We compared the endogenous expressions of miR-17
and miR-92 families in platinum-based chemotherapy-
resistant NSCLC tissues (NR tissues) and platinum-based
chemotherapy-sensitive NSCLC tissues (R tissues) by
RT–PCR. As shown in Fig. 6a, the analysis of mul-
tiple sets of comparable NR tissues and R tissues
showed that three miRNAs of miR-17 family (miR-17,
miR-20a and miR-20b) and three miRNAs of miR-92
family (miR-92a, miR-92b and miR-25) were less
abundant in NR tissues than in R tissues significantly
(P < 0.05). These results indicated that low expressions
of miR-17 and miR-92 families were positively corre-
lated with poorer therapeutic effect for NSCLC pa-
tients treated with platinum-based chemotherapy.
The potential of miR-17 and miR-92 families to
predict the clinical outcome of platinum-based chemo-
therapy was assessed by ROC analysis. When analyzed
as a continuous variable, the expression level of each
miRNA of miR-17 and miR-92 families could predict
the outcome of platinum-based chemotherapy (Fig. 6b).
When analyzed as a categorical variable, the expression
level of each miRNA was dichotomized and its categor-
ies represented by the score of 0 or 1, so that the com-
bined predictive ability of each family (three miRNAs)
or both two families (six miRNAs) could be assessed by
using the sum of scores as variables. The combined
score of both two families produced an AUC (Area
Under the Curve) of 0.79 (95 % CI 0.65–0.93) which
was higher than the score of individual family (Fig. 6b).
Moreover, according to the correlation analysis between
the expression levels of both two families (six miRNAs)
and the clinicopathological factors of NSCLC patients,
it was showed that the clinical outcome of cisplatin-
based chemotherapy was significantly correlated with
the expression levels of miR-17 and miR-92 families in
NSCLC tissues (Table 1). These data indicated that a
combined panel of miR-17 and miR-92 families could
be used as potential biomarkers for predicting the clinical
outcome of platinum-based chemotherapy in NSCLC.
Discussion
So far as we known, a lot of miRNAs have been impli-
cated in a wide variety of malignancies, miR-17 ~ 92
cluster and paralogous are no exception [25–27].
Germline deletion of miR-17 ~ 92 cluster leads to peri-
natal death of mutant mice with defective development
of the lung, heart and central nervous system, suggesting
that miR-17 ~ 92 cluster and paralogous play important
roles in many developmental processes [28–30]. It has
been found that miR-17-92 cluster is continued overex-
pressed during cancer development and is recognized as a
typical oncogene miRNA [31]. In lung cancer, high-
expression of miR-17-92 cluster also has been found re-
lated to worse prognosis [32]. In this study, compared
with cisplatin-sensitive A549 cells, the expressions of miR-
17 and miR-92 families are inhibited in the cisplatin-
resistant A549/DDP cells, suggesting that both miR-17
and miR-92 families play essential roles in cisplatin resist-
ance. Normally, the functional studies of miRNAs need to
focus on their target genes by which miRNAs regulate cell
functions [33]. Each miRNA may potentially influence
(See figure on previous page.)
Fig. 4 CDKN1A was a putative target gene in regulating G1 phase arrest and DNA synthesis. a Cell cycle of A549 cells and A549/DDP cells was
analyzed with FACS. The bar graphs showed the relative quantity of G1/S and G2/S ratio. b Cell cycle analysis of A549/DDP cells transfected with
miRNA mimics, siRNAs and NC controls. c EdU assay of A549/DDP cells transfected with miRNA mimics, siRNAs and NC controls. Hoechst stained
cells were blue and EdU add-in cells were rad. The bar graphs showed the relative quantity of cells incorporating EdU. At least 300 cells
Fig. 4 (See legend on next page.)
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more than 100 target genes and regulate cancer network
positively or negatively in a cellular context-dependent
manner [34]. In addition to the identification of TGFβR2
as a target gene for miR-17 family in the previous study
[20], here, we also have validated CDKN1A and RAD21 as
two other target genes for miR-17 family and miR-92 fam-
ily, revealing that miR-17 and miR-92 families form a
complicated regulatory network together with their target
genes in regulating cisplatin resistance.
In this study, we report that low expressions of
miR-17 and miR-92 families can be contributing to
cisplatin resistance by targeting CDKN1A and RAD21.
The cyclin-dependent kinase inhibitor, CDKN1A, is a
negative regulator of cell cycle progression in G1/S
checkpoint and is sufficient to arrest the entry of G1
phase cells into S phase [35, 36]. CDKN1A protein
can protect cancer cells from cisplatin-induced apop-
tosis as the DNA synthesis of S phase is reduced by
G1 arrest, suggesting that one major reason of caus-
ing cisplatin resistance is that low expression of miR-
17 family can block the DNA synthesis through
CDKN1A-induced G1 arrest. Furthermore, RAD21 is
an integral subunit of the cohesin complex involved
in holding sister chromatids together after DNA syn-
thesis until mitosis. Recent studies have suggested
that the cohesin complex is also involved in the DNA
Fig. 5 RAD21 was a putative target gene in regulating DNA repair. a Representative images showed γH2AX foci induced by cisplatin treatment,
and quantitative analyses showed more γH2AX foci in A549 cells than A549/DDP cells. b Quantitative analyses of γH2AX foci formation induced
by cisplatin in A549/DDP cells transfected with miRNA mimics, siRNAs and NC controls. c Quantitative analyses of γH2AX foci formation induced
by cisplatin in A549 cells transfected with mRNA protectors and NC controls. (n = 3, *P < 0.05)
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repair by tethering sister chromatids and provided
evidence that RAD21 can promote the DNA repair of
DSBs at G2 phase of cell cycle [37–39]. Therefore,
low expressions of miR-17 and miR-92 families can
enhance the RAD21-mediated DNA repair at G2 phase
for reducing the cisplatin-induced DNA damage during S
phase, resulting in causing cisplatin resistance. Our results
indicate that miR-17 and miR-92 families may synergistic-
ally regulate cisplatin resistance in complex ways, as the
regulatory function of their target genes can simultan-
eously inhibit DNA synthesis by G1 phase arrest and re-
pair DNA damage at G2 phase.
As a result of cisplatin-induced cytotoxicity in cancer
cells, DNA damage are induced by the formation of
DNA adducts during the process of DNA synthesis.
Therefore, cisplatin-induced cytotoxicity can be de-
creased by the inhibition of DNA synthesis and the
repair of DNA damage, and then cells stop cisplatin-
induced programmed suicide and become resistant to
cisplatin. Together with our previous results [20], it is
demonstrated that low expressions of miR-17 and
miR-92 families promote cisplatin resistance by acting
on multiple key effectors along triggering the inhib-
ition of DNA synthesis and the repair of DNA dam-
age, and this is achieved in part by targeting TGFβR2,
CDKN1A and RAD21 (Fig. 7). On the one hand, high
expressions of TGFβR2 and CDKN1A, which exist in
the same signaling pathway, can inhibit the cellular
proliferation by arresting cells at G1 phase, resulting
in the inhibition of active DNA synthesis at S phase
Fig. 6 The expressions of miR-17 and miR-92 families were associated with the clinical outcome of platinum-based chemotherapy. a Scatter plots
of expression levels of miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25 in responders and non-responders (NR, non-responder (stable
or progressive disease); R, responder (response or partial response)). (*P < 0.05) b ROC analysis assessing the association the expressions of
miR-17 and 92 families and the clinical outcome of platinum-based chemotherapy (NR or R) by miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25
levels as continuous variables, and combinations of miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25 levels using the sum of scores as categorical
variables, where each miRNA was dichotomised and its categories represented by the score of 0 or 1 as follows: score 0 (low risk) =miR-17, miR-20a,
miR-20b, miR-92a, miR-92b, miR-25 levels≥median; score 1(high risk) = converse of criteria for score 0
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Fig. 7 An illustrative summary of miR-17 and miR-92 families function on cisplatin resistance in NSCLC. miR-17 and miR-92 families function on
the inhibition of DNA synthesis and the repair of DNA damage by repressing CDKN1A and RAD21
Table 1 Correlation between the expressions of miR-17 and miR-92 families and the clinicopathological features of NSCLC patients
Clinicopathological factors Expression level of 6 miRNAsa χ2 value P value
High (n = 20) Low (n = 19)
Histological type Adenocarcinoma 12 10 0.216 0.642
Squamous carcinoma 8 9
Gender Male 14 15 0.407 0.523
Female 6 4
Age (years) <60 9 7 0.265 0.607
≥60 11 12
Smoking Nonsmoker 8 8 0.019 0.891
Smoker 12 11
TNM Clinical stage IIIB 5 8 1.288 0.256
IV 15 11
Chemotherapy regimensb DDP + TXT 9 6 0.745 0.689
DDP + GEM 6 7
DDP + NVB 5 6
Chemotherapy responsec CR + PR 7 13 4.366 0.036*
SD + PD 13 6
(* P < 0.05)
aExpression level of 6 miRNAs (miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25) was used the sum of scores as categorical variables, where each miRNA was
dichotomised and its categories represented by the score of 0 or 1 as follows: score 0 (low risk) = miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25 levels ≥
median; score 1(high risk) = converse of criteria for score 0
bDDP cisplatin, TXT docetaxel, GEM gemcitabine, NVB vinorelbine
cCR complete response, PR partial response, SD stable disease, PD progressive disease
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and the reduction of cisplatin-induced DNA damage
consequently. On the other hand, high expressions of
RAD21 can help cells to have more chances to repair
cisplatin-induced DNA damage during S phase. Thus,
under the cooperation of TGFβR2, CDKN1A and RAD21,
the inhibition of DNA synthesis and the repair of DNA
damage result in allowing cells to survival with the
burden of potentially lethal cisplatin-induced cytotox-
icity, and then cancer cells become resistant to cis-
platin. Our results suggest that the low expressions of
miR-17 and miR-92 families, which result in high ex-
pressions of TGFβR2, CDKN1A and RAD21, can syn-
ergistically inhibit DNA synthesis by induction of G1
phase arrest and reduce DNA damage by promotion
of DNA repair, so that cancer cells maintain cisplatin
resistance during chemotherapy.
We also identified that miR-17 and miR-92 families
are significantly associated with the clinical outcome of
platinum-based chemotherapy in NSCLC. Lower ex-
pression levels of miR-17 and miR-92 families in NSCLC
tissues were observed in platinum-based chemotherapy-
resistant patients compared with those in platinum-
based chemotherapy-sensitive patients. Other study
only assessed the higher levels of individual miR-92a-2*
are associated with chemotherapy resistance and with
decreased survival in patients with SCLC [40]. Here,
compared with single miR-17 family or miR-92 family,
the combined both of miR-17 and miR-92 families
have more potential to be early therapeutic response
biomarkers of platinum-based treatment in NSCLC.
This discrepancy is likely due to the combined regula-
tory effects of miR-17 and miR-92 families in cisplatin
resistance by simultaneously fine-tuning several genes.
Conclusions
Overall, in the current scope of our work, it is suggested
that miR-17 and miR-92 families can regulate cisplatin
resistance through the synergistic and combined regula-
tion of different targeted genes at the same time, such as
TGFβR2, CDKN1A and RAD21. Although we just have
studied two families of miR-17 ~ 92 cluster and paralo-
gous here, it is expected that perhaps there are more tar-
geted genes directly affected by other families, such as
miR-18 family and miR-19 family. Therefore, all miR-17
~ 92 families maybe participate in the control of their
target genes and form complicated regulation networks
together with their targeted genes to regulate chemo-
therapy resistance in NSCLC. Moreover, our study also
reveals miR-17 and miR-92 families have the potential to
predict the clinical outcome of platinum-based chemo-
therapy as molecular tumor biomarkers in NSCLC, and
it is also suggested that miR-17 and miR-92 families can
be used as potential therapeutic targets for reversing
platinum-based chemotherapy resistance.
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